AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37074807
Drug: 150 g
RxNorm normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 g mannitol
Trial: 33904329
Drug: Inoculation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inoculation with L. pseudotheobromae
Trial: 33904329
Drug: Inoculation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inoculation with L. theobromae
Trial: 32823839
Drug: Animal-Assisted Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animal-Assisted Therapy (AAT) with a therapy dog
Trial: 36169717
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clinical parameters and one-point MRD measurement
Trial: 34088338
Drug: Credelio Plus®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Credelio Plus® (lotilaner and milbemycin oxime) administered orally at a dose rate of 20.0-41.5 mg/kg bodyweight once every 4 weeks for 3 months
Trial: 34088338
Drug: Nexgard Spectra®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nexgard Spectra® (control product) administered as recommended once every 4 weeks for 3 months
Trial: 34088338
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (Credelio Plus® and Nexgard Spectra®)
Trial: 34743149
Drug: Nomogram based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomogram based on clinicopathologic variables (including ER+, PR+, HER2+ with Herceptin treatment, low ALNR) for predicting overall survival (OS)
Trial: 32517663
Drug: Nonavalent HPV
RxNorm normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonavalent HPV vaccination (3 injections)
Trial: 32517663
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections (NaCL 0.9%)
Trial: 34153136
Drug: Telephone-based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based Cognitive Behaviour Therapy (T-CBT)
Trial: 34153136
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual Cognitive Behaviour Therapy (TAU-CBT)
Trial: 32668111
Drug: Ticagrelor (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (180 mg loading dose followed by 90 mg twice daily) plus Aspirin (300 to 325 mg on the first day followed by 75 to 100 mg daily)
Trial: 32668111
Drug: Aspirin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (300 to 325 mg on the first day followed by 75 to 100 mg daily)
Trial: 38286485
Drug: Ticagrelor-aspirin
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor-aspirin
Trial: 35473729
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg prednisolone for 1 week
Trial: 35473729
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg prednisolone for 1 week
Trial: 35473729
Drug: 1.125 mg
RxNorm normalized name: Ascorbic Acid/Calcium Pantothenate/Folic Acid/Kava/Lecithin/Niacin/St John's Wort/Thiamine 60 MG-5 MG-0.1 MG-100 MG-15 MG-10 MG-225 MG-1.125 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.125 mg dexamethasone per day for 1 week
Trial: 35473729
Drug: 4.5 mg
RxNorm normalized name: phenol 14.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 mg dexamethasone per day for 1 week
Trial: 32370640
Drug: Real-world data
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real-world data (RWD) patients treated with the same therapy as the control arm
Trial: 33731270
Drug: Oral lefamulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lefamulin 600 mg every 12 h for 5 days
Trial: 33731270
Drug: Oral moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral moxifloxacin 400 mg every 24 h for 7 days
Trial: 34512011
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia and multi-modal analgesia (Control Group G)
Trial: 32217500
Drug: Mobile Interactive
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile Interactive Supervised Therapy (MIST)
Trial: 32809152
Drug: Initial medical
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial medical management (medical treatment based on anticoagulation, delayed by 24 hours if intravenous thrombolysis was performed)
Trial: 32603526
Drug: Roxadustat (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat (1 mg/kg)
Trial: 32603526
Drug: Roxadustat (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat (2 mg/kg)
Trial: 33545710
Drug: Dose-optimized radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose-optimized radiotherapy (DORT)
Trial: 32941265
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for ruptured AVMs
Trial: 34906127
Drug: Overall sample
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall sample (including treatment and control)
Trial: 32509046
Drug: Routine oral
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oral drugs and weekly paraspinal nerve block in C1 group.
Trial: 32509046
Drug: Routine oral
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oral drugs and weekly paraspinal nerve block in C2 group.
Trial: 33518062
Drug: Berberine (BBR)
RxNorm normalized name: berberine
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberine (BBR) 250 mg/kg
Trial: 33518062
Drug: Antibiotic positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic positive control (200 mg/kg oxytetracycline calcium and 250 mg/kg nasiheptide)
Trial: 32732773
Drug: Blood flow
RxNorm normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood flow restriction therapy on one arm
Trial: 32732773
Drug: Sham therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham therapy on the other arm
Trial: 32589648
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600 mg bid for eight weeks
Trial: 32589648
Drug: Standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses of rifampicin, isoniazid, pyrazinamide and ethambutol
Trial: 34984822
Drug: SGLT-2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT-2 inhibitor (empagliflozin)
Trial: 35232894
Drug: DA-9701 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA-9701 (30 mg, 3 times a day for 4 weeks)
Trial: 35101346
Drug: Cetuximab plus
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab plus avelumab (rechallenge therapy)
Trial: 33650779
Drug: Liraglutide (0.3–0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (0.3–0.9 mg/day)
Trial: 34419277
Drug: Milk replacer
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk replacer mixed with antirotavirus antibodies
Trial: 34419277
Drug: Colostrum replacer
RxNorm normalized name: COLOSTRUM
DrugBank: Human colostrum (DB19286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colostrum replacer mixed with antirotavirus antibodies
Trial: 34346165
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose of NL005 (0.05, 0.25, 0.5, 2.0, 5.0, 12.5 or 25.0 μg/kg)
Trial: 34346165
Drug: Multiple intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple intravenous doses of NL005 (0.5, 2.0 and 5.0 μg/kg) administered once daily for 10 days
Trial: 32989366
Drug: Various factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various factors associated with HPV vaccine hesitancy
Trial: 32586143
Drug: On-treatment HDL
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment HDL in the lowest quartile (≤ 1.21 mmol/l)
Trial: 32586143
Drug: On-treatment HDL
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment HDL in the second and third quartiles
Trial: 32586143
Drug: Baseline HDL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline HDL in the lowest quartile (≤ 1.21 mmol/l)
Trial: 32586143
Drug: On-treatment HDL
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment HDL in the lowest quartile
Trial: 32586143
Drug: Baseline HDL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline HDL ≤ 1.21 mmol/l
Trial: 33420951
Drug: Sorafenib-Pravastatin combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib-Pravastatin combination (Arm C)
Trial: 34847564
Drug: Exercise group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise group (group-exercise training once weekly and independent exercises at home twice weekly for 24 weeks)
Trial: 36162037
Drug: Nivolumab 240
RxNorm normalized name: nivolumab 240 MG in 24 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 240 mg once every 2 weeks plus ipilimumab 1 mg/kg once every 6 weeks
Trial: 36162037
Drug: Nivolumab 480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 480 mg once every 4 weeks
Trial: 32461038
Drug: No psychotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No psychotropic drugs
Trial: 32461038
Drug: ≥3 psychotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ≥3 psychotropic drugs
Trial: 32461038
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of antidepressant agents in mild and moderate dementia
Trial: 35995102
Drug: Study cigarettes
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study cigarettes (0.4, 2.4, 15.8 mg/g)
Trial: 35995102
Drug: 0.4 mg/g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/g nicotine content
Trial: 34283906
Drug: Weekly educational
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly educational SMS for 6 months
Trial: 32466811
Drug: Mentalization-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalization-based treatment plus treatment as usual (MBTp + TAU)
Trial: 32284053
Drug: 48 mg
RxNorm normalized name: betaine 648 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48 mg sucralose
Trial: 32284053
Drug: 96 mg
RxNorm normalized name: camphor 96 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 96 mg sucralose
Trial: 34498314
Drug: Infliximab plus
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab plus thiopurines (combination therapy)
Trial: 34498314
Drug: Overall cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall cohort (combination therapy vs. monotherapy)
Trial: 32957318
Drug: 10% hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% hypertonic saline (HTS), 0.63 ml/kg, administered as a bolus via a central venous catheter, infused over 15 minutes
Trial: 32957318
Drug: 20% mannitol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% mannitol, 2 ml/kg, administered as a bolus via a central venous catheter, infused over 15 minutes
Trial: 32508363
Drug: Adjunctive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive therapy with quetiapine or lamotrigine
Trial: 32508363
Drug: Monotherapy (lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (lithium or divalproex)
Trial: 34181506
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of measles‐mumps‐rubella (MMR) vaccine
Trial: 32676780
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g TXA via intravenous injection and 1 g TXA for external use (Group B)
Trial: 32676780
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rivaroxaban qd for 35 days after surgery (Group C)
Trial: 32676780
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of TXA and rivaroxaban (Group D)
Trial: 34365063
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg IM ketorolac
Trial: 34365063
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg IM ketorolac
Trial: 32380977
Drug: Andrographolide (AP)
RxNorm normalized name: Andrographolide
DrugBank: Andrographolide (DB05767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Andrographolide (AP) 140 mg orally twice daily for 24 months
Trial: 35537503
Drug: Left Atrial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left Atrial Appendage Occlusion (LAAO) with post-procedural dual antiplatelet therapy (DAPT)
Trial: 35537503
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antithrombotic therapy or DAPT as deemed appropriate)
Trial: 36878213
Drug: TAK-003 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-003 vaccine
Trial: 34504796
Drug: Dabrafenib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabrafenib (150 mg twice daily) plus Trametinib (2 mg once daily)
Trial: 35325846
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% lidocaine with paracetamol
Trial: 35325846
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% lidocaine with ibuprofen
Trial: 35325846
Drug: Oral paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral paracetamol alone
Trial: 32565458
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen alone
Trial: 32474062
Drug: Immediate restart
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Immediate restart of COC after taking UPA 30 mg
Trial: 32474062
Drug: Delayed restart
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Delayed restart of COC after taking UPA 30 mg
Trial: 33191835
Drug: Cyclosporine administered
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine administered by continuous intravenous infusion for 5 days in a novel Cremophor/Kolliphor EL-free lipid emulsion, NeuroSTAT
Trial: 33965603
Drug: CAL-DL-PDT (calcitriol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAL-DL-PDT (calcitriol followed by methyl aminolevulinate daylight photodynamic therapy)
Trial: 33965603
Drug: P-DL-PDT (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-DL-PDT (placebo followed by methyl aminolevulinate daylight photodynamic therapy)
Trial: 33653982
Drug: Erector spinae
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erector spinae plane block (ESPB) with 40 ml of ropivacaine 0.5% at T9 level bilaterally
Trial: 32495449
Drug: Remimazolam (RMZ)
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam (RMZ) 5 mg and 10 mg
Trial: 32495449
Drug: Midazolam (MDZ)
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam (MDZ) 2.5 mg and 5 mg
Trial: 35766126
Drug: Intravenous Regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Regional Anesthesia (IVRA)
Trial: 34081113
Drug: HMB (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB (1500 mg daily)
Trial: 32654242
Drug: Maca (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maca (2 g/day for 12 weeks)
Trial: 32654242
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 g/day for 12 weeks)
Trial: 36163944
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (n=18) in PRINCE study
Trial: 35940836
Drug: Intravenous beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous beta-blocker administration
Trial: 34738474
Drug: Music-guided exercise
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music-guided exercise intervention (n = 13), individualized music playlist, twice daily for 5 days.
Trial: 33891379
Drug: Bimekizumab (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimekizumab (320 mg every 4 weeks for 56 weeks)
Trial: 33891379
Drug: Adalimumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (40 mg every 2 weeks for 24 weeks, then bimekizumab every 4 weeks to week 56)
Trial: 33011968
Drug: Dual triggering
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual triggering with 10,000 units of hCG plus 0.2 mg of triptorelin
Trial: 34454260
Drug: Tapentadol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol (50 mg)
Trial: 34358344
Drug: FC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FC plus low-dose oxytocin
Trial: 33872652
Drug: Astegolimab 490
RxNorm normalized name: Astegolimab
DrugBank: Astegolimab (DB16386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astegolimab 490 mg
Trial: 33872652
Drug: Astegolimab 210
RxNorm normalized name: Astegolimab
DrugBank: Astegolimab (DB16386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astegolimab 210 mg
Trial: 33872652
Drug: Astegolimab 70
RxNorm normalized name: Astegolimab
DrugBank: Astegolimab (DB16386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astegolimab 70 mg
Trial: 33872652
Drug: Astegolimab 490
RxNorm normalized name: Astegolimab
DrugBank: Astegolimab (DB16386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astegolimab 490 mg (eosinophil-low)
Trial: 33872652
Drug: Astegolimab 210
RxNorm normalized name: Astegolimab
DrugBank: Astegolimab (DB16386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astegolimab 210 mg (eosinophil-low)
Trial: 33872652
Drug: Astegolimab 70
RxNorm normalized name: Astegolimab
DrugBank: Astegolimab (DB16386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astegolimab 70 mg (eosinophil-low)
Trial: 35363301
Drug: Samotolisib (LY3023414)
RxNorm normalized name: Samotolisib
DrugBank: LY-3023414 (DB12167)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Samotolisib (LY3023414) 200 mg twice daily plus enzalutamide 160 mg daily
Trial: 35363301
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus enzalutamide 160 mg daily
Trial: 33149022
Drug: Percutaneous tibial
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous tibial nerve stimulation plus medical treatment (arm A)
Trial: 33149022
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (arm B)
Trial: 36153028
Drug: Early Adolescent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early Adolescent Skills for Emotions (EASE) intervention, delivered in 7-weekly adolescent sessions and 3-biweekly caregiver sessions.
Trial: 32277824
Drug: upadacitinib 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: upadacitinib 7.5 mg
Trial: 33625673
Drug: Hydroxamate-based HDAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxamate-based HDAC inhibitors using receptor-dependent 4D-QSAR model
Trial: 33977947
Drug: 2S‐hesperidin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2S‐hesperidin (500 mg d‐1)
Trial: 33977947
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 mg d‐1 microcellulose)
Trial: 35236646
Drug: Butylphthalide treatment
RxNorm normalized name: Butylphthalide
DrugBank: Butylphthalide (DB12749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butylphthalide treatment
Trial: 33289028
Drug: Core Elements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Core Elements of Outpatient Antibiotic Stewardship implementation
Trial: 32621263
Drug: Life Review
RxNorm normalized name: Life-O-Gen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Life Review Therapy and Memory Specificity Training (LRT‐MST)